scispace - formally typeset
Journal ArticleDOI

Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism

Reads0
Chats0
TLDR
The results demonstrate the saturable transfer of L‐KYN across the blood–brain barrier and suggest that circulating L‐ KYN, 3‐HKYN, and ANA may each contribute significantly to respective cerebral pools under normal conditions.
Abstract
To evaluate the potential contribution of circulating kynurenines to brain kynurenine pools, the rates of cerebral uptake and mechanisms of blood-brain barrier transport were determined for several kynurenine metabolites of tryptophan, including L-kynurenine (L-KYN), 3-hydroxykynurenine (3-HKYN), 3-hydroxyanthranilic acid (3-HANA), anthranilic acid (ANA), kynurenic acid (KYNA), and quinolinic acid (QUIN), in pentobarbital-anesthetized rats using an in situ brain perfusion technique. L-KYN was found to be taken up into brain at a significant rate [permeability-surface area product (PA) = 2-3 x 10(-3) ml/s/g] by the large neutral amino acid carrier (L-system) of the blood-brain barrier. Best-fit estimates of the Vmax and Km of saturable L-KYN transfer equalled 4.5 x 10(-4) mumol/s/g and 0.16 mumol/ml, respectively. The same carrier may also mediate the brain uptake of 3-HKYN as D,L-3-HKYN competitively inhibited the brain transfer of the large neutral amino acid L-leucine. For the other metabolites, uptake appeared mediated by passive diffusion. This occurred at a significant rate for ANA (PA, 0.7-1.6 x 10(-3) ml/s/g), and at far lower rates (PA, 2-7 x 10(-5) ml/s/g) for 3-HANA, KYNA, and QUIN. Transfer for KYNA, 3-HANA, and ANA also appeared to be limited by plasma protein binding. The results demonstrate the saturable transfer of L-KYN across the blood-brain barrier and suggest that circulating L-KYN, 3-HKYN, and ANA may each contribute significantly to respective cerebral pools. In contrast, QUIN, KYNA, and 3-HANA cross the blood-brain barrier poorly, and therefore are not expected to contribute significantly to brain pools under normal conditions.

read more

Citations
More filters
Journal ArticleDOI

Phase-and disorder-specific differences in peripheral metabolites of the kynurenine pathway in major depression, bipolar affective disorder and schizophrenia.

TL;DR: In this paper , the authors investigated whether individual catabolites could serve as diagnostic biomarkers for mental disorders such as major depressive disorder (MDD), bipolar disorder (BD) or schizophrenia (SCZ).
Journal ArticleDOI

Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.

TL;DR: In this paper , a review of neuroactive kynurenine pathway metabolites, discuss the dysregulation of KP in aging and NDs and summarize the development of KP regulators in preclinical and clinical studies, offering an outlook of targeting KP for NDs treatment in future.
Journal ArticleDOI

Through the Looking-Glass: Psychoneuroimmunology and the Microbiome-Gut-Brain Axis in the Modern Antiretroviral Therapy Era

TL;DR: In this paper , a narrative review was conducted to integrate findings from 159 articles relevant to psychoneuroimmunology (PNI) and microbiome-gut-brain axis research in people with HIV.

Recent findings in kynurenine research in the field of experimental epilepsy and stroke models : Electrophysiological, behavioural and histological studies

TL;DR: Recent findings in kynurenine research in the field of experimental stroke models are reported on.
Journal ArticleDOI

Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE

TL;DR: In this article , the authors determined whether peripheral blood interferon-stimulated gene (ISG) expression associates with elevated serum kynurenine (KYN)/tryptophan (TRP) pathway metabolite, which can produce excitotoxic neuron damage.
References
More filters
Journal ArticleDOI

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

TL;DR: Intracerebral injection of the neuroexcitatory tryptophan metabolite, quinolinic acid, has behavioral, neurochemical and neuropathological consequences reminiscent of those of exogenous excitotoxins, such as kainic and ibotenic acids.
Journal ArticleDOI

Amino acid assignment to one of three blood-brain barrier amino acid carriers

TL;DR: Affinity for a basic amino acid carrier system was demonstrated for arginine, ornithine, and lysine and a third, low-capacity independent carrier system transporting aspartic and glutamic acids was demonstrated.
Journal ArticleDOI

An in situ brain perfusion technique to study cerebrovascular transport in the rat

TL;DR: The in situ brain perfusion technique is a sensitive new method to study cerebrovascular transfer in the rat and permits absolute control of perfusate composition.
Related Papers (5)